Zeyi Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zeyi Yang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alex J. Kalfa
Department of Cancer Biology, Keck School of Medicine, University of Southern California
5 shared publications - Ben Yi Tew
Department of Cancer Biology, Keck School of Medicine, University of Southern California, Los Angeles, USA
5 shared publications - Bodour Salhia
Department of Translational Genomics, Keck School of Medicine, University of Southern California and Norris Comprehensive Cancer Center, Los Angeles, USA
5 shared publications - Eric Abnoosian
Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, California
5 shared publications - Kyle Hurth
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California
5 shared publications - Petra Hamerlik
Division of Cancer Sciences & Geoffrey Jefferson Brain Research Centre, University of Manchester, Manchester
5 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Supplemental Figure 1. Immunochemistry (IHC) staining of γH2AX at experimental endpoint
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Supplemental Figure 1. Immunochemistry (IHC) staining of γH2AX at experimental endpoint
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Supplemental Figure 2. Gene set enrichment analysis (GSEA) of progression versus stable tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Supplemental Figure 2. Gene set enrichment analysis (GSEA) of progression versus stable tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Data from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Purpose:Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated inhibitor, as a radiosensitizer for breast cancer CM treatment.Experimental Design:Three patient-derived xenograft (PDX) tumors including 2 HER2+ and 1 triple-negative breast cancer harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain.Results:Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared with 123 days in controls. Administration of AZD1390 posttreatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50 to 100 days posttreatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment.Conclusions:Our results demonstrate that AZD1390 effectively sensitizes breast cancer CM to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CM.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Purpose:Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated inhibitor, as a radiosensitizer for breast cancer CM treatment.Experimental Design:Three patient-derived xenograft (PDX) tumors including 2 HER2+ and 1 triple-negative breast cancer harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain.Results:Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared with 123 days in controls. Administration of AZD1390 posttreatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50 to 100 days posttreatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment.Conclusions:Our results demonstrate that AZD1390 effectively sensitizes breast cancer CM to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CM.
- Open Access
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Data from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Purpose:Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated inhibitor, as a radiosensitizer for breast cancer CM treatment.Experimental Design:Three patient-derived xenograft (PDX) tumors including 2 HER2+ and 1 triple-negative breast cancer harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain.Results:Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared with 123 days in controls. Administration of AZD1390 posttreatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50 to 100 days posttreatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment.Conclusions:Our results demonstrate that AZD1390 effectively sensitizes breast cancer CM to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CM.
- 1 November 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Purpose:Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated inhibitor, as a radiosensitizer for breast cancer CM treatment.Experimental Design:Three patient-derived xenograft (PDX) tumors including 2 HER2+ and 1 triple-negative breast cancer harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain.Results:Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared with 123 days in controls. Administration of AZD1390 posttreatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50 to 100 days posttreatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment.Conclusions:Our results demonstrate that AZD1390 effectively sensitizes breast cancer CM to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CM.
- Open Access
- 16 August 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (21) , 4492-4503
ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Purpose: Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated inhibitor, as a radiosensitizer for breast cancer CM treatment. Experimental Design: Three patient-derived xenograft (PDX) tumors including 2 HER2+ and 1 triple-negative breast cancer harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain. Results: Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared with 123 days in controls. Administration of AZD1390 posttreatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50 to 100 days posttreatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment. Conclusions: Our results demonstrate that AZD1390 effectively sensitizes breast cancer CM to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CM.
- 16 August 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (21) , 4492-4503
Open AccessATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Purpose: Limited effective treatments are currently available for central nervous system (CNS) metastasis (CM). This is largely driven by the inability of current therapeutics to penetrate the blood brain barrier (BBB) and the lack of preclinical models for testing new therapies. Here we study the efficacy of AZD1390, a BBB penetrating ataxia-telangiectasia mutated inhibitor, as a radiosensitizer for breast cancer CM treatment. Experimental Design: Three patient-derived xenograft (PDX) tumors including 2 HER2+ and 1 triple-negative breast cancer harboring DNA damage response (DDR) gene mutations, were implanted subcutaneously in the flank of mice to assess tumor growth inhibition by AZD1390 combined with radiation. Animal survival was further assessed by implanting the best responding PDX model orthotopically in the brain. Results: Pretreatment with AZD1390 followed by radiation therapy inhibited growth of PDX tumors implanted in the flank, and improved survival in orthotopic models with average survival of 222 days compared with 123 days in controls. Administration of AZD1390 posttreatment for 21 days had no further benefits. While the combination therapy resulted in sustained tumor inhibition, sporadic regrowth was observed in some mice 50 to 100 days posttreatment in all models. Gene expression comparing these tumors with complete responders demonstrated changes in upregulation of oncogenic proteins, which are potential drivers of tumor growth after treatment. Conclusions: Our results demonstrate that AZD1390 effectively sensitizes breast cancer CM to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CM.
- 1 June 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 69-74
Design and Control of Multi-mode Wheeled-Bipedal Robot with Parallel Mechanism
Wheeled-bipedal robot is a kind of mobile robot to combine the advantages of wheeled and legged locomotion. However, existing wheeled bipedal robots often require effort to overcome gravity while they do not need to maintain a standing position all the time. Therefore, we design a multimode motor-driven wheeled-bipedal robot SUSTech-Nezha II to explore the fusion of wheel and leg. The robot has two mirror symmetric legs with a total of six degrees of freedom. A novel five-bar linkage mechanism has been integrated into the design of the leg for the purpose of transmission. The robot has two modes of motion: the wheeled-bipedal mode and the four-wheel mode. The robot primarily operates in the four-wheel mode, as it provides superior stability and energy efficiency compared to the wheeled-bipedal mode. The latter mode is only utilized when height adjustments are necessary. This paper introduces the design and control methods of the overall robotic system. The control strategy for seamless mode switching is also developed. Finally, we verify the feasibility of the whole system through several hardware experiments.
- 1 June 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 69-74
Design and Control of Multi-mode Wheeled-Bipedal Robot with Parallel Mechanism
Wheeled-bipedal robot is a kind of mobile robot to combine the advantages of wheeled and legged locomotion. However, existing wheeled bipedal robots often require effort to overcome gravity while they do not need to maintain a standing position all the time. Therefore, we design a multimode motor-driven wheeled-bipedal robot SUSTech-Nezha II to explore the fusion of wheel and leg. The robot has two mirror symmetric legs with a total of six degrees of freedom. A novel five-bar linkage mechanism has been integrated into the design of the leg for the purpose of transmission. The robot has two modes of motion: the wheeled-bipedal mode and the four-wheel mode. The robot primarily operates in the four-wheel mode, as it provides superior stability and energy efficiency compared to the wheeled-bipedal mode. The latter mode is only utilized when height adjustments are necessary. This paper introduces the design and control methods of the overall robotic system. The control strategy for seamless mode switching is also developed. Finally, we verify the feasibility of the whole system through several hardware experiments.